Dong-Wook Kim

2 weeks ago | nature.com | Andreas Hochhaus |Dong-Wook Kim |Jorge Cortés |Koji Sasaki |Michael J. Mauro |Timothy Hughes | +7 more

AbstractAsciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerability, and antileukemic activity of asciminib in 115 patients with chronic myeloid leukemia in chronic phase without the BCR::ABL1T315I mutation who received asciminib 10–200 mg twice daily (BID) or 80–200 mg once daily (cutoff: March 14, 2023).

Nov 2, 2023 | biorxiv.org | George Mountoufaris |Aditya Nair |Dong-Wook Kim |David Anderson

AbstractInternal states drive survival behaviors, but their neural implementation is not well understood. Recently we identified a line attractor in the ventromedial hypothalamus (VMH) that represents an internal state of aggressiveness. Line attractors can be implemented by recurrent connectivity and/or neuromodulatory signaling, but evidence for the latter is scant.